Psychemedics Corp provides forensic drug testing solutions to employers and government entities while managing a significant cash burn through share repurchases and operational losses.
Despite recent losses, the company maintains a strong balance sheet with $1.4M in cash equivalents and significant non-controlling equity of $15.3M, suggesting potential for turnaround if revenue stabilizes. The forensic drug testing sector remains essential for workplace safety compliance, offering recurring revenue streams from long-term employer contracts.
The company has suffered three consecutive years of declining revenue and deepening losses, with the accumulated deficit reaching -$18.6M by 2024. High administrative costs and aggressive share repurchases without corresponding profitability growth signal potential financial distress and unsustainable capital allocation strategies.
Psychemedics Corp is a clinical laboratory specializing in forensic drug testing services for employers, healthcare providers, and government agencies across North America. The company leverages advanced analytical technologies to detect substances of abuse, serving the occupational health, insurance verification, and legal markets. Recent financials reflect operations driven by high-volume testing contracts and strategic capital allocation efforts.
The company reported a net loss of $1.9M in 2024 following a decline in revenue from $25.2M in 2022 to $19.7M in 2024, indicating shrinking market share or pricing pressure. While operating cash flow was positive at $929,000 due to non-cash adjustments and working capital changes, the company utilized financing flows to repurchase shares totaling $2.6M while burning cash overall.
The forensic drug testing industry is essential for maintaining workplace safety standards and insurance fraud prevention, though it faces margin compression from payer consolidation and regulatory changes. Competition is moderate but high barriers to entry exist due to the need for certified laboratories and proprietary analytical methods.
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $25.2M | $22.1M | $19.7M |
| Cost of Revenue | $15.9M | $13.7M | $12.6M |
| Gross Profit | $9.3M | $8.4M | $7.1M |
| Operating Expenses | $10.4M | $11.3M | $9.0M |
| Operating Income | $-1.1M | $-2.9M | $-1.9M |
| R&D | $1.3M | $1.1M | $749.0K |
| G&A | $5.9M | $7.2M | $5.7M |
| Marketing | $3.2M | $3.0M | $2.5M |
| Stock-Based Comp | $872.0K | $908.0K | $917.0K |
| D&A | $2.4M | $1.7M | $1.1M |
| Other OpEx | $0 | $0 | $0 |
| Non-Operating Income | $43.0K | $-517.0K | $-23.0K |
| Interest Expense | $32.0K | $17.0K | $26.0K |
| Interest Income | $0 | $0 | $0 |
| Pre-Tax Income | $-1.0M | $-3.4M | $-1.9M |
| Income Tax | $44.0K | $716.0K | $-55.0K |
| Continuing Ops | $-1.1M | $-4.2M | $-1.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-1.1M | $-4.2M | $-1.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-1.1M | $-4.2M | $-1.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $10.0M | $6.8M | $4.9M |
| Cash & Equivalents | $4.8M | $2.0M | $1.4M |
| Accounts Receivable | $3.7M | $3.7M | $2.5M |
| Prepaid Expenses | $1.1M | $1.1M | $997.0K |
| Other Current Assets | $339.0K | $18.0K | $24.0K |
| Long-Term Assets | $8.8M | $5.5M | $3.4M |
| PP&E (Net) | $4.6M | $3.1M | $2.0M |
| Operating Leases | $2.7M | $1.8M | $844.0K |
| Other LT Assets | $1.5M | $632.0K | $535.0K |
| Total Assets | $18.7M | $12.3M | $8.3M |
| Current Liabilities | $5.7M | $4.7M | $2.7M |
| Accounts Payable | $448.0K | $752.0K | $462.0K |
| Current Debt | $294.0K | $305.0K | $0 |
| Current Leases | $1.0M | $1.0M | $452.0K |
| Other Current Liab | $0 | $0 | $237.0K |
| Long-Term Liabilities | $2.2M | $945.0K | $477.0K |
| Long-Term Debt | $305.0K | $0 | — |
| LT Operating Leases | $1.9M | $945.0K | $424.0K |
| Other LT Liab | $0 | $0 | $53.0K |
| Total Liabilities | $8.0M | $5.7M | $3.2M |
| Shareholders' Equity | $10.8M | $6.7M | $5.1M |
| Retained Earnings | $-11.8M | $-16.8M | $-18.6M |
| AOCI | $-1.6M | $-1.6M | $-1.6M |
| Treasury Stock | $10.1M | $10.1M | $10.1M |
| Total L&E | $18.7M | $12.3M | $8.3M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-1.1M | $-4.2M | $-1.9M |
| Non-Cash Adjustments | $9.1M | $3.4M | $5.2M |
| Working Capital Changes | $-3.1M | $-760.0K | $-2.4M |
| Cash from Operations | $4.9M | $-1.5M | $929.0K |
| Capital Expenditures | $187.0K | $157.0K | $51.0K |
| Cash from Investing | $-208.0K | $-159.0K | $-87.0K |
| Share Buybacks | — | — | $2.6M |
| Dividends Paid | $1.2M | $799.0K | $0 |
| Cash from Financing | $-1.9M | $-1.1M | $-1.4M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $2.8M | $-2.8M | $-547.0K |
| Beginning Cash | $2.0M | $4.8M | $2.0M |
| Ending Cash | $4.8M | $2.0M | $1.4M |
Forensic Drug Testing Services, Occupational Health Solutions, Insurance Verification Programs, and Government/Defense Contracts.
Persistent net losses exacerbating the accumulated deficit of $18.6M, aggressive share buybacks reducing capital reserves despite negative operating cash flow, declining revenue trend over the last three years, and high general and administrative expenses relative to gross profit.
Proprietary analytical technologies for accurate substance detection, established long-term contracts with major employers and government bodies, and a diversified client base spanning multiple industries.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.